Guardant Health, Inc.
NASDAQ:GHMedical - Diagnostics & Research
+$2.67 today
- Market cap
- $19.64B
- Beta
- 1.62
- P/E (TTM)
- -39.9
- EPS (TTM)
- -$3.30
Volume 1.50M
Average 2.21M
GH Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Guardant Health, Inc.NASDAQ: GH
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $124.36M (cash outflow) rose 34.1% year over year, ahead of the +21.6% change in trailing-twelve-month net income. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Net income amounted to 42.4% of revenue in FY2025, down 16.7 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 19 analysts of -$429.41M (+3.2%) for the fiscal year ending Dec 2026, a step up from the -4.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$124.36M+3.5% QoQ
- Last fiscal yearDec 2025
- -$416.28M-4.6% YoY
- LTMSep 2026
- -$485.07M+21.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +34.1% | -21.7% | -55.8 pp |
| 1 year | -4.6% | +3.2% | +7.8 pp |
| 3-year CAGR | -14.0% | -39.2% | -25.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (416.28M) USD
- Year-over-year change
- +4.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (416.28M) | +4.6% |
| FY2024 | 2024-12-31 | (436.37M) | +9.0% |
| FY2023 | 2023-12-31 | (479.45M) | +26.8% |
| FY2022 | 2022-12-31 | (654.59M) | -70.1% |
| FY2021 | 2021-12-31 | (384.77M) | — |
Net Income vs competitors
How GH compares with its peers on the latest reported figures
- GH's LTM Sep 2026 net income of $485.07M is the largest of the 10 companies compared; the peer median is $74.56M.
- Its year-over-year change of +21.6% is the 4th highest of 9, against a peer median of +1.0%.
- Net income amounts to 37.9% of revenue for GH, versus a peer median of 23.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $485.07M | +21.6% | -14.0% | 37.9% | |
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Jun 2026 | $391.59M | -11.6% | -57.7% | 236.9% | |
| LTM Jun 2026 | $192.35M | -24.0% | -27.6% | 7.1% | |
| LTM Mar 2026 | $95.55M | +13.7% | -10.5% | 148.1% | |
| LTM Mar 2026 | $74.56M | +78.1% | — | 23.3% | |
| LTM Jun 2026 | $51.88M | -50.1% | -9.2% | 6.8% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $37.71M | — | — | 9.5% |
| LTM Mar 2026 | $31.96M | -20.9% | -18.6% | 33.3% | |
| LTM Mar 2026 | $12.83M | +153.1% | -28.9% | 3.8% | |
| Peer median (excluding GH) | $74.56M | +1.0% | -18.6% | 23.3% | |
Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (384.77M) | (654.59M) | (479.45M) | (436.37M) | (416.28M) |
| Depreciation & Amortization | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 151.45M | 94.69M | 90.76M | 140.41M | 166.22M |
| Change in Working Capital | (40.47M) | 61.56M | 53.84M | (60.86M) | (14.43M) |
| Accounts Receivables | (44.35M) | 375K | 8.38M | (21.39M) | (28.18M) |
| Inventory | (7.96M) | (20.93M) | (10.35M) | (9.14M) | (14.79M) |
| Accounts Payables | 8.64M | 60.33M | 0 | 0 | 0 |
| Other Working Capital | 3.2M | 21.79M | 55.81M | (30.34M) | 28.54M |
| Other Non-Cash Items | 42.5M | 152.91M | (33.01M) | 74.58M | 39.99M |
| Operating Cash Flow | (209.02M) | (309.46M) | (324.98M) | (239.86M) | (184.76M) |
| Capital Expenditures | (75.04M) | (77.46M) | (20.49M) | (35.09M) | (48.31M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (58.99M) |
| Purchases of Investments | (940.23M) | (327.72M) | (635.5M) | (314.82M) | (827.23M) |
| Sales of Investments | 952.11M | 555M | 1.5B | 88.6M | 307.32M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (63.16M) | 149.82M | 840.25M | (261.31M) | (627.2M) |
| Debt Repayment | (146K) | (71K) | 0 | 0 | 402.5M |
| Common Stock Issued | 0 | 0 | 493.12M | 14.84M | 377.81M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (45.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (66.68M) | (189.02M) | (15.74M) | (15.83M) | (64.17M) |
| Financing Cash Flow | (66.82M) | (189.09M) | 477.38M | (996K) | 671.13M |
| Effect of Forex Changes | (1.69M) | (1.6M) | (911K) | (1.77M) | 491K |
| Net Change in Cash | (340.69M) | (350.34M) | 991.74M | (503.93M) | (140.34M) |
| Free Cash Flow | (284.05M) | (386.92M) | (345.46M) | (274.94M) | (233.07M) |
Guardant Health, Inc.
NASDAQ:GH
Intrinsic Alpha fair value
Locked
Current Price
$145.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.